Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
In July, Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) priced its upsized initial public offering of 13.92 million shares at $12.00 per share, with gross proceeds of approximately $167.0 million.
7月，Artiva Biotherapeutics, Inc.（纳斯达克股票代码：ARTV）将其扩大的1392万股首次公开募股定价为每股12.00美元，总收益约为1.670亿美元。
Artiva is a clinical-stage biotechnology company focused on developing cell therapies for patients with devastating autoimmune diseases and cancers.
Artiva是一家临床阶段的生物技术公司，专注于为患有毁灭性自身免疫性疾病和癌症的患者开发细胞疗法。
Artiva's lead program, AlloNK, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion.
Artiva的主要项目AllonK是一种异基因、现成的、非基因改造、冷冻保存的Nk细胞疗法候选药物，旨在增强单克隆抗体的抗体依赖性细胞毒性作用，从而推动b细胞消耗。
AlloNK is currently in clinical trials for systemic lupus erythematosus, patients with or without lupus nephritis, and an investigator-initiated basket trial in multiple autoimmune indications.
AllonK目前正在对系统性红斑狼疮、有或没有狼疮肾炎的患者进行临床试验，以及一项由研究者发起的针对多种自身免疫适应症的篮子试验。
Artiva's pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers.
Artiva的产品线还包括针对实体癌和血液系统癌的CAR-NK候选药物。
Needham initiates coverage on Artiva and says, "Artiva is developing what we view as scalable cellular therapeutics for autoimmune disorders."
Needham开始对Artiva进行报道，并说：“Artiva正在开发我们认为可扩展的自身免疫性疾病细胞疗法。”
Needham notes that initial clinical results from the lupus study are expected in 2025, most probably in the first half of 2025. The analyst also sees AlloNK in lupus as the main near-term driver for Artiva.
尼德姆指出，狼疮研究的初步临床结果预计将在2025年公布，很可能在2025年上半年。该分析师还将狼疮中的AllonK视为Artiva的主要短期驱动力。
A Needham analyst estimates that AlloNK could achieve approximately $1.7 billion in global sales for treating systemic lupus erythematosus (SLE) and lupus nephritis (LN) by 2038, capturing around 20% of the market. The analyst also notes that several other companies are developing cellular therapies for SLE and LN, including other NK cell programs.
尼德姆的一位分析师估计，到2038年，AllonK在治疗系统性红斑狼疮（SLE）和狼疮肾炎（LN）方面的全球销售额可能达到约17亿美元，占据约20％的市场份额。该分析师还指出，其他几家公司正在开发SLE和LN的细胞疗法，包括其他Nk细胞项目。
Needham has initiated with a Buy rating and a price target of $23.
Needham最初的评级为买入，目标股价为23美元。
Wedbush also initiated coverage on Artiva Biotherapeutics, noting that the company's cell therapy is straightforward to manufacture and deliver and adaptable to different targets.
Wedbush还开始对Artiva Biotherapeutics进行报道，指出该公司的细胞疗法易于制造和交付，并且可以适应不同的靶标。
Recent studies have confirmed that various cell-based therapies are effective for different autoimmune conditions, showing a link between B-cell depletion and symptom improvement.
最近的研究证实，各种基于细胞的疗法对不同的自身免疫性疾病有效，表明b细胞消耗与症状改善之间存在联系。
Wedbush initiated with an Outperform rating with a price target of $18.
Wedbush最初的评级为跑赢大盘，目标股价为18美元。
"Given the level of B-cell depletion achieved in Artiva's B-NHL study, we believe AlloNK has the potential to drive deep and durable remissions in B-cell dependent autoimmune diseases," Wedbush analyst added.
Wedbush分析师补充说：“鉴于Artiva的b-NHL研究达到的b细胞消耗水平，我们认为AllonK有可能推动b细胞依赖性自身免疫性疾病的深度持久缓解。”
Price Action: ARTV stock is down 0.36% at $11.18 at last check Tuesday.
价格走势：周二最后一次检查时，ARTV股价下跌0.36％，至11.18美元。
Photo via Shutterstock
照片来自 Shutterstock
- Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug.
- 法官裁定诺华停止其最畅销的心脏病药物的仿制药上市。